INTRODUCTION
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene, initially described in 2004, are the most prevalent genetic cause of Parkinson disease (PD), and have been associated with both familial and sporadic cases of PD in some populations. (1, 2) Although at least seven distinct pathogenic mutations in LRRK2 have been proven to cause PD, there is considerable population variability in the frequencies of these mutations. ( 3) The most common is the LRRK2 p.G2019S substitution, with a global frequency of 1% in sporadic PD and up to 5% in familial PD. (4) The highest frequencies of LRRK2 p.G2019S mutations are reported from the North African Berber and Arab populations, where it is present in 30-42% of familial PD, 30-39% of apparently sporadic PD, and 0-2.2% of healthy controls. (5) The interest in exploring genetic underpinnings to PD extend beyond elucidating pathogenetic mechanisms, to ultimately manipulating the knowledge to derive viable disease modifying and therapeutic targets. Following evidence of gain-of-function increase in LRRK2 kinase activity in mutation carriers, promising pre-clinical studies have already demonstrated neuroprotective properties of LRRK2 kinase inhibitors, including reduced alpha-synuclein aggregation, reduced dopaminergic neurodegeneration, and reduced microglial and macrophage activation. (6) Considering the enormous potential future application to LRRK2 p.G2019S -related PD, determining the relevance in diverse populations is imperative.
Although comprehensively studied in numerous European and North American populations, studies on the frequency of LRRK2 p.G2019S in sub-Saharan Africa have been scarce. A previous report from our Nigerian African population including 4 57 sporadic PD patients and 51 healthy controls did not identify LRRK2 p.G2019S mutations in either PD cases or controls. (7) In this study we aimed at exploring a larger cohort of PD cases and healthy controls from a Black African Nigerian background for the LRRK2 p.G2019S mutation to further clarify the role of this mutation in PD in sub Saharan Africans. accordance with the protocol, written informed consent was obtained from all participants, and included permission to re-contact for future studies. Clinical data from hard-copy case record forms were logged into a secure database. All data was de-identified to protect confidentiality, and assigned a unique study code and given a unique laboratory code. Clinical variables were analysed using the IBM ® Statistical Package for Social Sciences (SPSS) ® version 21. Chi-square test and analysis of variance test were used to compare categorical parameters and age respectively between PD cases and controls. Level of significance was set at a p value <0.05. Genotypes were examined for deviation from Hardy-Weinberg equilibrium using Chisquare test.
DNA extraction and LRRK2 p.G2019S genotyping

RESULTS
Baseline clinical characteristics of PD cases and controls
The baseline characteristics of the PD cases and controls are shown in Table 1 . The study included 126 PD cases and 54 controls with comparable mean ages (years) at the time of the study (61.9 ± 9.9 and 64.6 ± 8.7 respectively) (ANOVA; p=0.14). The median age at onset of PD was 59.0 years, while median duration of PD was 48 months. A family history of parkinsonism or tremor in a first degree relative was present in 20 (15.9%) of the PD and none of the controls (as this was an exclusion criterion for controls).
LRRK2 G2019S mutation analysis in PD cases and controls
The LRRK2 p.G2019S mutation was absent in all subjects. All 126 PD patients and 54 controls were homozygous for the p.G2019S (GG) normal allele. Allelic frequencies for p.G2019S (rs34637584) SNP were in Hardy-Weinberg equilibrium (P = 1). KASP assay performed very well. 100% call rates was achieved with clear genotyping clusters and no ambiguous calls.
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DISCUSSION
The data from this second cohort of PD from Nigeria corroborate the conclusions from our earlier publication that the commonest pathogenic mutation in LRRK2, (itself the commonest genetic cause of both familial and sporadic PD) the p.G2019S mutation, observed in several different populations, is not a frequent cause of PD in Nigeria. (7) This is similar to the view from other studies in the black populations of sub Saharan Africa, and in contrast to the data from Northern African Arab and Berber populations. In a small cohort study from Zambia (east Africa), the p.G2019S mutation was absent in 39 PD patients (10) , as was the observation in another group of 54 PD patients and 46 controls from Ghana (west Africa). (11) In a study of 205 South African PD patients from varied backgrounds (42% Caucasian, 31% Afrikaner, 17% mixed ancestry, 8% Black and 2% Indian), LRRK2 p.G2019S mutation was not found in Afrikaner and Black South African patients. Only 2% of patients (three Caucasian and one patient from a mixed ancestry) were found to be carriers (12) . All batteries developed for PD in the future, will have improved yield, and genetic counselling will be developed with content relevant to the sub Saharan African population. In addition, such data will provide a basis for expanding our understanding of the genetics mechanisms contributing to PD in our population.
Our study utilized a rigorous clinical and laboratory methodology for case ascertainment and genotyping respectively. Diagnosis of PD was based on the MDS criteria, and all cases also fulfilled the UKPD Brain Bank criteria, verified in person by two neurologists specializing in movement disorders. With respect to the genotyping, the KASP is considered to be a reliable and more cost-effective genotyping assay for p.G2019S screening than multiplex methods, with the added advantage of being time-effective. (18) We conclude that the contribution of genetics to the causation of PD in sub Saharan Africa remain unclear and largely unexplored. The region offers the unique advantage of having the greatest diversity of polymorphisms than any other world region, and this can be explored through adequately funded collaborative studies. Hoehn and Yahr stage at study (range) 1 -5
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